Institute of Pharmacy and Food Chemistry, University of Würzburg, Würzburg, Germany.
DSTL, Defence Science and Technology Laboratory, Salisbury, UK.
Arch Pharm (Weinheim). 2024 Aug;357(8):e2400032. doi: 10.1002/ardp.202400032. Epub 2024 Apr 30.
Due to increasing antibiotic resistance, the development of anti-infectives with new mechanisms of action is crucial. Virulence factors such as the "macrophage infectivity potentiator" (Mip) protein, which catalyzes the folding of proline-containing proteins by means of their cis-trans isomerase (PPIase) activity, have come into focus as a potential new target. Since the inhibition of Mip by small molecules has been shown to lead to reduced virulence and survival in vitro, especially of Gram-negative bacteria such as Burkholderia pseudomallei (Bp), Neisseria meningitidis (Nm), and Neisseria gonorrhoeae (Ng), or Coxiella burnetii (Cb), among many others, a library of Mip inhibitors was developed. As drug metabolism has a significant impact on the overall therapeutic outcome, this report describes the biotransformation of the most potent Mip inhibitors. Therefore, the anti-infectives were treated using human liver microsomes in vitro. Liquid chromatography with tandem mass spectrometry (LC/MS-MS) methods were applied to identify the metabolites and quantify the metabolic degradation of the hit compounds. Active metabolites, N-oxides, were found, leading to new opportunities for further drug development.
由于抗生素耐药性的不断增加,开发具有新作用机制的抗感染药物至关重要。毒力因子如“巨噬细胞感染增强因子”(Mip)蛋白,通过其顺式-反式异构酶(PPIase)活性催化脯氨酸含量蛋白的折叠,已成为一个潜在的新靶标。由于小分子抑制 Mip 已被证明可导致体外毒力和存活能力降低,尤其是革兰氏阴性细菌,如伯克霍尔德氏菌假单胞菌(Bp)、脑膜炎奈瑟菌(Nm)和淋病奈瑟菌(Ng)或柯克斯体伯氏菌(Cb)等,因此开发了 Mip 抑制剂库。由于药物代谢对整体治疗效果有重大影响,本报告描述了最有效的 Mip 抑制剂的生物转化。因此,使用人肝微粒体在体外处理抗感染药物。应用液相色谱-串联质谱(LC/MS-MS)方法鉴定代谢物并定量测定命中化合物的代谢降解。发现了活性代谢物 N-氧化物,为进一步药物开发提供了新的机会。